{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:44:39Z","timestamp":1787067879812,"version":"build-2736575974"},"reference-count":80,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260898"],"award-info":[{"award-number":["82260898"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.heliyon.2024.e30393","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T21:25:10Z","timestamp":1714166710000},"page":"e30393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Advancements on the impact of hydroxychloroquine in systemic lupus erythematosus"],"prefix":"10.1016","volume":"10","author":[{"given":"Liu","family":"Peng-Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lv","family":"Meng-Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Jian-Bin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Shu-Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0110-4912","authenticated-orcid":false,"given":"Rui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e30393_bib1","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/01.md.0000091181.93122.55","article-title":"European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine","volume":"82","author":"Cervera","year":"2003","journal-title":"Baltimore"},{"key":"10.1016\/j.heliyon.2024.e30393_bib2","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211073001","article-title":"Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge","volume":"14","author":"Dima","year":"2022","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.heliyon.2024.e30393_bib3","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","article-title":"American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision)","volume":"123","author":"Marmor","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.heliyon.2024.e30393_bib4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2125.1988.tb05281.x","article-title":"A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers","volume":"26","author":"Tett","year":"1988","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e30393_bib5","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2165\/00003088-199631040-00003","article-title":"Clinical pharmacokinetics and metabolism of chloroquine. Focus. On. Recent. advancements","volume":"31","author":"Ducharme","year":"1996","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.heliyon.2024.e30393_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0002-9343(83)91265-2","article-title":"Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate","volume":"75","author":"McChesney","year":"1983","journal-title":"Am. J. Med."},{"key":"10.1016\/j.heliyon.2024.e30393_bib7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1146\/annurev-physiol-012110-142317","article-title":"Lysosomal acidification mechanisms","volume":"74","author":"Mindell","year":"2012","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.heliyon.2024.e30393_bib8","first-page":"23","article-title":"Chloroquine and hydroxychloroquine inhibit multiple sites in metabolic pathways leading to neutrophil superoxide release","volume":"15","author":"Hurst","year":"1988","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.heliyon.2024.e30393_bib9","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/jps.20792","article-title":"Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications","volume":"96","author":"Kaufmann","year":"2007","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.heliyon.2024.e30393_bib10","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1126\/science.1204592","article-title":"TFEB links autophagy to lysosomal biogenesis","volume":"332","author":"Settembre","year":"2011","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30393_bib11","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1159\/000484955","article-title":"Chloroquine autophagic inhibition rebalances Th17\/Treg-mediated immunity and ameliorates systemic lupus erythematosus","volume":"44","author":"An","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.heliyon.2024.e30393_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.972397","article-title":"Hydroxychloroquine attenuates autoimmune hepatitis by suppressing the interaction of GRK2 with PI3K in T lymphocytes[J]","volume":"13","author":"Jin","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e30393_bib13","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/1744666X.2019.1624527","article-title":"Additive immunosuppressive effect of leflunomide and hydroxychloroquine supports rationale for combination therapy for Sj\u00f6gren's syndrome","volume":"15","author":"van der Heijden","year":"2019","journal-title":"Expet Rev. Clin. Immunol."},{"key":"10.1016\/j.heliyon.2024.e30393_bib14","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1073\/pnas.79.1.175","article-title":"Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells","volume":"79","author":"Ziegler","year":"1982","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.heliyon.2024.e30393_bib15","first-page":"55","article-title":"Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells","volume":"24","author":"van","year":"1997","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.heliyon.2024.e30393_bib16","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0306-3623(97)00269-3","article-title":"Antimalarial drugs inhibit phospholipase A2 activation and induction of interleukin 1beta and tumor necrosis factor alpha in macrophages: implications for their mode of action in rheumatoid arthritis","volume":"30","author":"Bondeson","year":"1998","journal-title":"Gen. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e30393_bib17","doi-asserted-by":"crossref","first-page":"766","DOI":"10.6061\/clinics\/2013(06)07","article-title":"Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients","volume":"68","author":"Silva","year":"2013","journal-title":"Clinics. Sao. Paulo."},{"key":"10.1016\/j.heliyon.2024.e30393_bib18","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1002\/art.22157","article-title":"Antimalarial agents: closing the gate on Toll-like receptors?","volume":"54","author":"Lafyatis","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.heliyon.2024.e30393_bib19","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.4049\/jimmunol.1402793","article-title":"Cutting edge: antimalarial drugs inhibit IFN-\u03b2 production through blockade of cyclic GMP-AMP synthase-DNA interaction","volume":"194","author":"An","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.heliyon.2024.e30393_bib20","doi-asserted-by":"crossref","DOI":"10.1111\/aji.13686","article-title":"Hydroxychloroquine protects against autoimmune premature ovarian insufficiency by modulating the Treg\/Th17 cell ratio in BALB\/c mice","volume":"89","author":"Shuai","year":"2023","journal-title":"Am. J. Reprod. Immunol."},{"key":"10.1016\/j.heliyon.2024.e30393_bib21","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/art.27289","article-title":"The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus","volume":"62","author":"Jung","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.heliyon.2024.e30393_bib22","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/0961203306071872","article-title":"Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus","volume":"15","author":"Ruiz-Irastorza","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.heliyon.2024.e30393_bib23","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/ard.2008.093013","article-title":"Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort","volume":"68","author":"Kaiser","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.heliyon.2024.e30393_bib24","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3899\/jrheum.161351","article-title":"Longterm hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus","volume":"44","author":"Fasano","year":"2017","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.heliyon.2024.e30393_bib25","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/art.41621","article-title":"Association of higher hydroxychloroquine blood levels with reduced thrombosis risk in systemic lupus erythematosus","volume":"73","author":"Petri","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.heliyon.2024.e30393_bib26","doi-asserted-by":"crossref","DOI":"10.1177\/20406223231160688","article-title":"Risk factors of significant relapse and appropriate maintenance therapy strategy in SLE-associated immune thrombocytopenia","volume":"14","author":"Li","year":"2023","journal-title":"Ther. Adv. Chronic. Dis."},{"key":"10.1016\/j.heliyon.2024.e30393_bib27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0304-4165(85)90202-8","article-title":"Mepacrine (quinacrine) inhibition of thrombin-induced platelet responses can be overcome by lysophosphatidic acid","volume":"842","author":"McCrea","year":"1985","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.heliyon.2024.e30393_bib28","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1161\/01.CIR.96.12.4380","article-title":"Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice","volume":"96","author":"Edwards","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.heliyon.2024.e30393_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102863","article-title":"Mechanistic insight into premature atherosclerosis and cardiovascular complications in systemic lupus erythematosus","volume":"132","author":"Liu","year":"2022","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.heliyon.2024.e30393_bib30","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/178721","article-title":"Imbalance between endothelial damage and repair: a gateway to cardiovascular disease in systemic lupus erythematosus","volume":"2014","author":"Mak","year":"2014","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.heliyon.2024.e30393_bib31","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.cmet.2006.10.002","article-title":"ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome","volume":"4","author":"Schneider","year":"2006","journal-title":"Cell Metabol."},{"key":"10.1016\/j.heliyon.2024.e30393_bib32","first-page":"e95","article-title":"Effects of low-dose hydroxychloroquine on expression of phosphorylated Akt and p53 proteins and cardiomyocyte apoptosis in peri-infarct myocardium in rats","volume":"18","author":"Zhou","year":"2013","journal-title":"Exp. Clin. Cardiol."},{"key":"10.1016\/j.heliyon.2024.e30393_bib33","doi-asserted-by":"crossref","DOI":"10.1097\/CRD.0000000000000547","article-title":"Hydroxychloroquine and cardiotoxicity","author":"Dey","year":"2023","journal-title":"Cardiol. Rev."},{"key":"10.1016\/j.heliyon.2024.e30393_bib34","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1139\/y98-146","article-title":"Insulin-sparing effect of hydroxychloroquine in diabetic rats is concentration dependent","volume":"77","author":"Emami","year":"1999","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e30393_bib35","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1093\/rheumatology\/keu451","article-title":"Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study","volume":"54","author":"Chen","year":"2015","journal-title":"Rheumatology. Oxford"},{"key":"10.1016\/j.heliyon.2024.e30393_bib36","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1007\/s00125-015-3689-2","article-title":"Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial","volume":"58","author":"Wasko","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.heliyon.2024.e30393_bib37","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1124\/mol.112.079152","article-title":"Molecular mechanisms of chloroquine inhibition of heterologously expressed Kir6.2\/SUR2A channels","volume":"82","author":"Ponce-Balbuena","year":"2012","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e30393_bib38","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1515\/JPEM.2010.23.7.709","article-title":"Down-regulation of Kir6.2 affects calcium influx and insulin secretion in HIT-T15 cells","volume":"23","author":"Chen","year":"2010","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"10.1016\/j.heliyon.2024.e30393_bib39","first-page":"68","article-title":"Dyslipidemia in patients with systemic lupus erythematosus: association with disease activity and B-type natriuretic peptide levels. Biomed","volume":"4","author":"Yuan","year":"2016","journal-title":"Repura"},{"key":"10.1016\/j.heliyon.2024.e30393_bib40","article-title":"Impact of antimalarial (AM) on serum lipids in systemic lupus erythematosus (SLE) patients: a systematic review and meta-analysis","volume":"98","author":"Tao","year":"2019","journal-title":"Medicine. Baltimore."},{"key":"10.1016\/j.heliyon.2024.e30393_bib41","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1177\/0961203312450084","article-title":"Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect","volume":"21","author":"Cairoli","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.heliyon.2024.e30393_bib42","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1191\/096120300678828541","article-title":"Hydroxychloroquine has no significant effect on lipids and apolipoproteins in Chinese systemic lupus erythematosus patients with mild or inactive disease","volume":"9","author":"Tam","year":"2009","journal-title":"Lupus"},{"key":"10.1016\/j.heliyon.2024.e30393_bib43","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1177\/0961203319851558","article-title":"Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort","volume":"28","author":"Geraldino-Pardilla","year":"2019","journal-title":"Lupus"},{"key":"10.1016\/j.heliyon.2024.e30393_bib44","article-title":"A reference range of hydroxychloroquine blood levels that can reduce odds of active lupus and prevent flares","author":"Garg","year":"2023","journal-title":"Arthritis. Care. Res. Hoboken"},{"key":"10.1016\/j.heliyon.2024.e30393_bib45","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1007\/s00431-023-04837-0","article-title":"Hydroxychloroquine in children with proliferative lupus nephritis: a randomized clinical trial","volume":"182","author":"Gheet","year":"2023","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.heliyon.2024.e30393_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102864","article-title":"Pregnancy-related complications in systemic lupus erythematosus","volume":"132","author":"Tan","year":"2022","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.heliyon.2024.e30393_bib48","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1136\/annrheumdis-2017-212535","article-title":"Effect of pregnancy on disease flares in patients with systemic lupus erythematosus","volume":"77","author":"Eudy","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.heliyon.2024.e30393_bib51","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S1473-3099(03)00806-5","article-title":"Effects of chloroquine on viral infections: an old drug against today's diseases?","volume":"3","author":"Savarino","year":"2003","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e30393_bib52","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0042-6822(90)90099-D","article-title":"Acidotropic amines inhibit proteolytic processing of flavivirus prM protein","volume":"174","author":"Randolph","year":"1990","journal-title":"Virology"},{"key":"10.1016\/j.heliyon.2024.e30393_bib56","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/nrendo.2014.35","article-title":"Autophagy--a key player in cellular and body metabolism","volume":"10","author":"Kim","year":"2014","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.heliyon.2024.e30393_bib47","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jaut.2017.02.009","article-title":"Impact of systemic lupus erythematosus on maternal and fetal outcomes following pregnancy: a meta-analysis of studies published between years 2001-2016","volume":"79","author":"Bundhun","year":"2017","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.heliyon.2024.e30393_bib49","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1111\/jcmm.17459","article-title":"X. Protection by hydroxychloroquine prevents placental injury in obstetric antiphospholipid syndrome","volume":"26","author":"Liu","year":"2022","journal-title":"J. Cell Mol. Med."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e30393_bib50","first-page":"3640","article-title":"Hydroxychloroquine in lupus pregnancy","volume":"54","author":"Clowse","year":"2006","journal-title":"Arthritis Rheum. 2006 Nov"},{"key":"10.1016\/j.heliyon.2024.e30393_bib53","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1167\/iovs.10-5278","article-title":"Induction of lysosomal dilatation, arrested autophagy, and cell death by chloroquine in cultured ARPE-19 cells","volume":"51","author":"Yoon","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.heliyon.2024.e30393_bib54","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.ijrobp.2013.07.024","article-title":"Chloroquine engages the immune system to eradicate irradiated breast tumors in mice","volume":"87","author":"Ratikan","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.heliyon.2024.e30393_bib55","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.imlet.2013.07.004","article-title":"Chloroquine: modes of action of an undervalued drug","volume":"153","author":"Thom\u00e9","year":"2013","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.heliyon.2024.e30393_bib57","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/imj.12100","article-title":"A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus","volume":"43","author":"Carmichael","year":"2013","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.heliyon.2024.e30393_bib58","first-page":"1199","article-title":"Monitoring plasma hydroxychloroquine concentration and its application in patients with systemic lupus erythematosus","volume":"41","author":"Liu","year":"2022","journal-title":"Medical. Journal. Of. Chinese. People's. Liberation. Army."},{"key":"10.1016\/j.heliyon.2024.e30393_bib59","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1002\/art.22156","article-title":"Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus","volume":"54","author":"Costedoat-Chalumeau","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.heliyon.2024.e30393_bib60","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/FTD.0000000000000261","article-title":"Population pharmacokinetics of hydroxychloroquine in Japanese patients with cutaneous or systemic lupus erythematosus","volume":"38","author":"Morita","year":"2016","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.heliyon.2024.e30393_bib61","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13075-020-02211-1","article-title":"Measurement of hydroxychloroquine in blood from SLE patients using LC-HRMS-evaluation of whole blood, plasma, and serum as sample matrices","volume":"22","author":"Carlsson","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.heliyon.2024.e30393_bib62","first-page":"1127","article-title":"Metabolism and interactions of chloroquine and hydroxychloroquine with human cytochrome P450 enzymes and drug transporters","volume":"21","author":"Rendic","year":"2020","journal-title":"Curr. Drug Metabol."},{"key":"10.1016\/j.heliyon.2024.e30393_bib63","first-page":"513","article-title":"Impact of genetic polymorphism on hydroxychloroquine blood concentrations in patients with systemic lupus erythematosus","volume":"35","author":"Zhong","year":"2019","journal-title":"Chinese. Journal. Of. Clinical. Pharmacology"},{"key":"10.1016\/j.heliyon.2024.e30393_bib64","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1136\/annrheumdis-2021-221295","article-title":"Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort","volume":"81","author":"Almeida-Brasil","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.heliyon.2024.e30393_bib65","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3390\/ph14030273","article-title":"Evaluation of hydroxychloroquine blood concentrations and effects in childhood-onset systemic lupus erythematosus","volume":"14","author":"Zahr","year":"2021","journal-title":"Pharmaceuticals. Basel."},{"key":"10.1016\/j.heliyon.2024.e30393_bib67","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1177\/0961203319851558","article-title":"Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort","volume":"28","author":"Geraldino-Pardilla","year":"2019","journal-title":"Lupus"},{"key":"10.1016\/j.heliyon.2024.e30393_bib68","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.3899\/jrheum.150379","article-title":"Hydroxychloroquine blood levels in systemic lupus erythematosus: clarifying dosing controversies and improving adherence","volume":"42","author":"Durcan","year":"2015","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.heliyon.2024.e30393_bib69","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/ndt\/gfx318","article-title":"Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome?","volume":"33","author":"Cunha","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.heliyon.2024.e30393_bib70","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.3899\/jrheum.151094","article-title":"Routine hydroxychloroquine blood concentration measurement in systemic lupus erythematosus reaches adulthood","volume":"42","author":"Costedoat-Chalumeau","year":"2015","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.heliyon.2024.e30393_bib71","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1136\/annrheumdis-2012-202322","article-title":"Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study)","volume":"72","author":"Costedoat-Chalumeau","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.heliyon.2024.e30393_bib66","article-title":"Subtherapeutic hydroxychloroquine concentration is associated with increased disease activity and greater organ damage in lupus","volume":"19","author":"Kang","year":"2023","journal-title":"Rheumatology. Oxford)."},{"key":"10.1016\/j.heliyon.2024.e30393_bib72","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/07853890.2020.1839959","article-title":"Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019","volume":"53","author":"Bansal","year":"2021","journal-title":"Ann. Med."},{"key":"10.1016\/j.heliyon.2024.e30393_bib73","first-page":"294","article-title":"Ocular toxicity of hydroxychloroquine. Hong. Kong","volume":"12","author":"Yam","year":"2006","journal-title":"Med. J."},{"key":"10.1016\/j.heliyon.2024.e30393_bib74","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","article-title":"The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy","volume":"132","author":"Melles","year":"2014","journal-title":"JAMA. Ophthalmol."},{"key":"10.1016\/j.heliyon.2024.e30393_bib75","doi-asserted-by":"crossref","unstructured":"Marmor, M.F., Kellner, U., Lai, T.Y., Melles, R.B., Mieler, W.F., and American Academy of Ophthalmology. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology. 123, 1386-1394. https:\/\/doi.org\/10.1016\/j.ophtha.2016.01.058..","DOI":"10.1016\/j.ophtha.2016.01.058"},{"key":"10.1016\/j.heliyon.2024.e30393_bib76","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/art.41121","article-title":"Hydroxychloroquine blood levels predict hydroxychloroquine retinopathy","volume":"72","author":"Petri","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.heliyon.2024.e30393_bib77","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1093\/rheumatology\/keaa157","article-title":"Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis","volume":"59","author":"Lenfant","year":"2020","journal-title":"Rheumatology. Oxford"},{"key":"10.1016\/j.heliyon.2024.e30393_bib78","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S1473-3099(18)30415-8","article-title":"Chloroquine as weekly chemoprophylaxis or intermittent treatment to prevent malaria in pregnancy in Malawi: a randomised controlled trial","volume":"18","author":"Divala","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e30393_bib79","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/ard.2004.023200","article-title":"Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients","volume":"65","author":"Casado","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.heliyon.2024.e30393_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.616075","article-title":"Chloroquine and hydroxychloroquine myopathy: clinical spectrum and treatment outcomes","volume":"11","author":"Naddaf","year":"2021","journal-title":"Front. Neurol."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024064247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024064247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T11:04:26Z","timestamp":1775732666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024064247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":80,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2405844024064247"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e30393","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancements on the impact of hydroxychloroquine in systemic lupus erythematosus","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e30393","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e30393"}}